Stringent structural requirements for anti-Ras activity of S-prenyl analogues

被引:49
作者
Aharonson, Z
Gana-Weisz, M
Varsano, T
Haklai, R
Marciano, D
Kloog, Y [1 ]
机构
[1] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel
[2] Israel Inst Biol Res, IL-70450 Ness Ziona, Israel
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 1998年 / 1406卷 / 01期
基金
以色列科学基金会;
关键词
Ras oncoproteins; Ras-antagonists; farnesyl analog; geranylgeranyl analog; EJ cell line;
D O I
10.1016/S0925-4439(97)00077-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The carboxy terminal S-farnesylcysteine of Ras oncoproteins is required for their membrane anchorage and transforming activities. We showed previously that S-farnesylthiosalicylic acid (FTS) affects the membrane anchorage of activated H-Ras in EJ cells and inhibits their growth. We report here on structural elements in S-prenyl derivatives that specifically inhibit the growth of EJ cells, but not of untransformed Rat-1 cells. inhibition of the Ras-dependent extracellular signal-regulated protein kinase (ERK), of DNA synthesis and of EJ cell growth were apparent after treatment with FTS or its 5-fluoro, 5-chloro and 4-fluoro derivatives or with the C-20 S-geranylgeranyl derivative of thiosalicylic acid. The 4-Cl-FTS analogue was a weak inhibitor of EJ cell growth. The 3-Cl-FTS analogue and the FTS carboxyl methyl ester were inactive, as were the C-10 S-geranyl derivative of thiosalicylic acid, farnesol, farnesoic acid, N-acetyl-S-farnesyl-L-cysteine and S-farnesylthiopropionic acid. The structural requirements for anti-Ras activity of S-prenyl analogues thus appear to be rather stringent. With regard to chain length, the C-15 farnesyl group linked to a rigid backbone seems to be necessary and sufficient. A free carboxyl group in an appropriately rigid orientation, as in thiosalicylic acid, is also required. Halogenic substituents on the benzene ring of the thiosalicylic acid are tolerated only at position 5 or 4. This information may facilitate the design of potent Ras antagonists and deepen our understanding of the mode of association of Ras with the plasma membrane. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:40 / 50
页数:11
相关论文
共 36 条
[1]   RAF MEETS RAS - COMPLETING THE FRAMEWORK OF A SIGNAL-TRANSDUCTION PATHWAY [J].
AVRUCH, J ;
ZHANG, XF ;
KYRIAKIS, JM .
TRENDS IN BIOCHEMICAL SCIENCES, 1994, 19 (07) :279-283
[2]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[3]   THE UNIQUELY DISTRIBUTED ISOPRENYLATED PROTEIN METHYLTRANSFERASE ACTIVITY IN THE RAT-BRAIN IS HIGHLY EXPRESSED IN THE CEREBELLUM [J].
BENBARUCH, G ;
PAZ, A ;
MARCIANO, D ;
EGOZI, Y ;
HAKLAI, R ;
KLOOG, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 195 (01) :282-288
[4]   PROTEINS REGULATING RAS AND ITS RELATIVES [J].
BOGUSKI, MS ;
MCCORMICK, F .
NATURE, 1993, 366 (6456) :643-654
[6]   P21RAS IS MODIFIED BY A FARNESYL ISOPRENOID [J].
CASEY, PJ ;
SOLSKI, PA ;
DER, CJ ;
BUSS, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (21) :8323-8327
[8]   HOW MAP KINASES ARE REGULATED [J].
COBB, MH ;
GOLDSMITH, EJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (25) :14843-14846
[9]   SPECIFIC ISOPRENOID MODIFICATION IS REQUIRED FOR FUNCTION OF NORMAL, BUT NOT ONCOGENIC, RAS PROTEIN [J].
COX, AD ;
HISAKA, MM ;
BUSS, JE ;
DER, CJ .
MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (06) :2606-2615
[10]  
Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W